or Try an Advanced Search...

    Technical Analysis for RNAZ - TransCode Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.34 2.50% 0.01
    RNAZ closed up 2.5 percent on Wednesday, November 20, 2024, on 12 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical RNAZ trend table...
    Date Alert Name Type % Chg
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    NR7 Range Contraction 2.50%
    NR7-2 Range Contraction 2.50%
    Narrow Range Bar Range Contraction 2.50%
    Wide Bands Range Expansion 2.50%
    Down 3 Days in a Row Weakness 2.50%
    Down 4 Days in a Row Weakness 2.50%
    Down 5 Days in a Row Weakness 2.50%
    Older End-of-Day Signals for RNAZ ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 20 hours ago
    Up 3% about 20 hours ago
    Up 2% about 20 hours ago
    Up 1% about 20 hours ago
    Possible NR7 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    RNAZ Chart by TradingView
    Basic chart:

    Profile

    TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Preclinical Stage Product Metastatic Cancer

    Is RNAZ a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 12 TransCode Therapeutics Open Letter to Shareholders
    Nov 5 TransCode Therapeutics gets Nasdaq extension to regain compliance
    Nov 5 TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
    Oct 23 TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
    Oct 10 TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
    Sep 17 TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
    Sep 5 TransCode Therapeutics secures $2M grant for lead candidate
    Sep 5 TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
    Aug 15 TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
    Jul 29 Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
    See more RNAZ news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 18.48
    52 Week Low 0.216
    Average Volume 1,703,153
    200-Day Moving Average 0.66
    50-Day Moving Average 0.50
    20-Day Moving Average 0.45
    10-Day Moving Average 0.38
    Average True Range 0.06
    RSI (14) 32.89
    ADX 18.34
    +DI 19.25
    -DI 31.11
    Chandelier Exit (Long, 3 ATRs) 0.60
    Chandelier Exit (Short, 3 ATRs) 0.49
    Upper Bollinger Bands 0.65
    Lower Bollinger Band 0.26
    Percent B (%b) 0.19
    BandWidth 84.01
    MACD Line -0.06
    MACD Signal Line -0.04
    MACD Histogram -0.0169
    Fundamentals Value
    Market Cap 355.15 Thousand
    Num Shares 1.06 Million
    EPS -652.00
    Price-to-Earnings (P/E) Ratio 0.00
    Price-to-Sales 0.00
    Price-to-Book 0.16
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.36
    Resistance 3 (R3) 0.36 0.35 0.36
    Resistance 2 (R2) 0.35 0.35 0.35 0.36
    Resistance 1 (R1) 0.35 0.34 0.34 0.35 0.36
    Pivot Point 0.34 0.34 0.33 0.34 0.34
    Support 1 (S1) 0.33 0.33 0.32 0.33 0.32
    Support 2 (S2) 0.32 0.32 0.32 0.31
    Support 3 (S3) 0.31 0.32 0.31
    Support 4 (S4) 0.31